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Abstract
Background: Dysregulation of the immune system has been shown to occur during spaceflight, although the
detailed nature of the phenomenon and the clinical risks for exploration class missions have yet to be established.
Also, the growing clinical significance of immune system evaluation combined with epidemic infectious disease
rates in third world countries provides a strong rationale for the development of field-compatible clinical
immunology techniques and equipment. In July 2002 NASA performed a comprehensive immune assessment on
field team members participating in the Haughton-Mars Project (HMP) on Devon Island in the high Canadian
Arctic. The purpose of the study was to evaluate the effect of mission-associated stressors on the human immune
system. To perform the study, the development of techniques for processing immune samples in remote field
locations was required. Ten HMP-2002 participants volunteered for the study. A field protocol was developed at
NASA-JSC for performing sample collection, blood staining/processing for immunophenotype analysis, whole-
blood mitogenic culture for functional assessments and cell-sample preservation on-location at Devon Island.
Specific assays included peripheral leukocyte distribution; constitutively activated T cells, intracellular cytokine
profiles, plasma cortisol and EBV viral antibody levels. Study timepoints were 30 days prior to mission start, mid-
mission and 60 days after mission completion.
Results: The protocol developed for immune sample processing in remote field locations functioned properly.
Samples were processed on Devon Island, and stabilized for subsequent analysis at the Johnson Space Center in
Houston. The data indicated that some phenotype, immune function and stress hormone changes occurred in the
HMP field participants that were largely distinct from pre-mission baseline and post-mission recovery data. These
immune changes appear similar to those observed in astronauts following spaceflight.
Conclusion: The immune system changes described during the HMP field deployment validate the use of the
HMP as a ground-based spaceflight/planetary exploration analog for some aspects of human physiology. The
sample processing protocol developed for this study may have applications for immune studies in remote
terrestrial field locations. Elements of this protocol could possibly be adapted for future in-flight immunology
studies conducted during space missions.
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Background
The growing diagnostic significance of clinical immunol-
ogy combined with epidemic microbial disease rates in
third-world countries make it clear that improved field-
laboratory capabilities may be needed in the future to sup-
portimmune testing or research. Whereas technological
advances have already made it possible to provide field-
testing for other laboratory disciplines (chemistry, hema-
tology, etc.), field immunology research has remained a
challenge. This is due in part to the labile nature of
cytokines and chemokines, the requirement for high-
quality cellular samples with surface antigen integrity
intact, and in some cases the need for live cell cultures.
The size, weight and power requirements of most of the
required instrumentation (incubators, flow cytometers,
etc.) also largely preclude their routine use in the field.
Dysregulation of the immune system has been docu-
mented to occur during spaceflight. There have been sev-
eral excellent reviews published regarding this
phenomenon [1-4]. Specific post-flight or in-flight
changes observed include alterations in cytokine produc-
tion patterns [5-14], NK cell function [15-17], leukocyte
distribution [6,18], reactivation of latent herpes viruses
[19-22], monocyte function [23,24], neutrophil function
[25,18], T cell intracellular signaling [26-30], neuorendo-
crine responses [31] and leukocyte proliferation following
activation [32,33]. Spaceflight-associated immune dys-
function may be due to flight-related factors (micrograv-
ity, fluid shifts, radiation) or mission-associated factors
(confinement, isolation, physiologic stress, nutrition,
altered circadian rhythms, altered microbial environment,
etc.) not uniquely associated with spaceflight. NASA is
currently performing studies to investigate the causes and
clinical risk associated with prolonged spaceflight-associ-
ated immune dysregulation in astronauts, prior to the ini-
tiation of exploration class missions. Aside from
microgravity, many of the challenges in performing in-
flight immune studies are similar to those faced by per-
sonnel performing clinical medicine in remote field loca-
tions or third-world countries. These challenges include
isolation, difficulty in transporting laboratory equipment,
power requirements, reagent stability, as well as the integ-
rity of processed and stored biological samples.
To evaluate the effects of mission-associated factors on
human physiology, ground-based 'spaceflight analogs'
may be used [34]. A variety of analogs are available, each
unique and exerting some influence on human physiol-
ogy that is similar to one (or more) aspects of space flight.
For ground-based studies, it is very important to choose
the analog that is most appropriate for the physiological
system of interest. Examples of such analogs are extended
bed rest (for fluid shifts, bone and muscle loss), closed
chamber confinement (for psychological and isolation
issues) and Antarctic winter-over (for isolation, confine-
ment and stress). An excellent ground based flight analog
for immune studies would simulate mission-associated
stress, isolation and disrupted circadian rhythms. During
Antarctic winter-over, subjects experience prolonged iso-
lation in a harsh extreme environment, and several com-
prehensive immune studies have been conducted during
these expeditions. Antarctic immune studies have shown
decreased cell mediated immune responses [35-37],
reduced T cell function [38], altered cytokine production
profiles [38-40] and latent herpesvirus reactivation
[37,38]. A study of antibody production following immu-
nization during winter over found no alterations mid mis-
sion [41], potentially indicating humoral immunity is
unchanged in the presence of altered cellular immunity.
Thus, the Antarctic analog has been the most successful to
date in simulating spaceflight-associated immune dysreg-
ulation.
The NASA Haughton-Mars Project (HMP) is an interna-
tional field research project centered on the scientific
study of the Haughton meteorite impact structure and sur-
rounding terrain on Devon Island, Nunavut Territory,
Canadian High Arctic. The HMP is viewed as an analog for
planetary exploration, in particular for exploration of the
Moon and Mars (figure 1) [42]. Haughton crater is the
only impact crater on Earth set in a true polar desert (figure
2): an environment that is cold (annual average T is -
16°C), dry (annual precipitation is < 13 mm), windy,
rocky, sparsely vegetated, and receiving a high solar UV
flux in the summer. The HMP supports an exploration
program focused on defining the requirements, and on
developing the technologies and strategies, needed for
planning future robotic and human planetary missions.
The HMP is particularly well suited for exploration-related
human physiology studies because field personnel are
subject to actual and  relevant environmental stressors,
although clearly not as extreme as those encountered in
space. In addition, they are engaged in field exploration
tasks that in many cases are direct analogs to those antici-
pated for the Moon and Mars. Activities at HMP are driven
by actual field exploration and research agendas, not sim-
ulations thereof, which makes the surface operations, les-
sons learned and the human experience acquired
particularly valuable. The following factors encountered
by HMP field participants are particularly relative to
spaceflight/planetary exploration:
• Long travel to and from Devon Island (several days of
travel followed by weeks of stay)
• Relatively harsh polar desert environment
• Disrupted circadian rhythms (24 hours of daylight dur-
ing the Summer field season)BMC Immunology 2007, 8:7 http://www.biomedcentral.com/1471-2172/8/7
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• Relative isolation from the outside world (with limited
exception)
• Limited local infrastructure (HMP Research Station is
analogous to early lunar or Martian outpost)
• Moon and Mars-relevant (analog) exploration/field/
EVA activities
• Reliance on remote telemedicine and communications
equipment.
These factors make the HMP potentially a good analog for
spaceflight-associated immune dysfunction studies. The
objectives of the present study were to (1) develop and
field-evaluate methods for processing biological samples
to support immune function testing in remote locations;
and (2) utilize the protocol to assess mission-associated
immune changes during a HMP mission. These methods
could be adapted for monitoring the immune system of
astronauts during exploration-class spaceflight or for
immunology research studies in third-world/field loca-
tions.
For this study, a deployment to the HMP Research Station
was carried out in July 2002, during which a mobile bio-
logical sample processing facility was established in the
station's laboratory tent facility. A panel of assays was
developed that would comprehensively assess for each
participant: (1) the presence or absence of specific
immune responses; (2) the functional responsiveness
immune system; (3) the presence or absence of latent EBV
reactivation; (4) physiological stress. Ten subjects
deployed to Devon Island during the 2002 field season
participated in the study (figure 3). The specific assays
were as follows:
1. Peripheral blood immunophenotype/leukocyte subset
distribution.
2. Constitutive activation status of T cell subsets.
Sample collection dates vs. field season activity for all ten  study subjects Figure 3
Sample collection dates vs. field season activity for all ten 
study subjects. Participants are on-location at Devon Island 
for varying lengths of time, depending on the individual sub-
ject's mission objectives. In general, the field season lasts for 
approximately one month each summer. Sample consisted of 
20 ml whole blood. Pre- and post-mission samples were col-
lected at local clinics and overnight shipped to JSC for analy-
sis. Field samples were processed on-location (including cell 
culture) and stabilized for transport to JSC.
(A) Map indicating the location of the HMP research Station  on Devon Island, Canadian High Arctic Figure 1
(A) Map indicating the location of the HMP research Station 
on Devon Island, Canadian High Arctic. The home locations 
of the 10 HMP study participants are also indicated (green 
circles). (B) Airborne synthetic aperture radar image of 
Haughton Crater acquired in 1998 by the Intera STAR X-
band radar system. The width of the scene is 36 km. The cra-
ter is approximately 20 km wide. North is up. Image courtesy 
Geological Survey of Canada and HMP.
Overview photo showing the HMP Research Station and sur- rounding area at the time the study was conducted (Summer,  2002) Figure 2
Overview photo showing the HMP Research Station and sur-
rounding area at the time the study was conducted (Summer, 
2002). The tent area in the foreground served as personal liv-
ing quarters for HMP field participants. Immediately behind is 
the central base camp, consisting of core facilities, laboratory 
space, communications and mess tent, etc. The prototype 
Mars greenhouse is located to the left of the core facility. 
The rim of the impact crater is distant-right. The FMARS 
habitat, located on the crater rim, was not used in this study.BMC Immunology 2007, 8:7 http://www.biomedcentral.com/1471-2172/8/7
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3. T cell cytokine production profiles.
4. EBV-specific humoral responses.
5. EBV-direct plasma viral DNA via PCR.
6. Plasma cortisol levels.
Results
Field sample processing
Cytometry revealed that the integrity of the mid-mission
whole blood samples remained acceptable for analysis
despite the in-field processing and the lengthy delay until
analysis. This was true both for immunophenotype sam-
ples and cytometry analysis of the cells activated during
culture. Although a mild elevation in green auto fluores-
cence was observed following analysis, all desired sub-
populations could be resolved using multi-color and
immunoscatter back-gating strategies to eliminate any
artifactual debris (Figure 4). In addition, no observable
degradation in sample was observed for any of the assays
which used EDTA plasma as a sample (antibody levels,
viral DNA, cortisol). Although it would be difficult to dis-
tinguish legitimate mid-mission changes from degraded
sample for these assays, no degradation was expected, as
field processing (removal of plasma) was not markedly
different from standard laboratory processing. Also, the
analytes for these assays are known to be stable for dura-
tion required prior to analysis. In contrast, the cytometry
analysis of individual processed cells inherently allows an
assessment of sample integrity during analysis.
Peripheral immunophenotype
For the 10 HMP participants in this study, mean percent-
ages of the leukocyte subsets, lymphocyte subsets and T
cell subsets demonstrated no significant mid-mission
alterations (figure 5a). When cytotoxic CD8+ T cell sub-
sets were resolved based on the expression of CD28 and
CD244 (C1.7), a significant increase in the active cyto-
toxic population (CD28+/CD244+) was observed, corre-
sponding with a significant decrease in the non-
differentiated population (CD28+/CD244-) (figure 5b).
'Major' memory and naïve T cell subsets were assessed
based on the expression of cell surface CD45RA. There
were no observable mid-mission differences in the levels
of either naïve CD4+ T cells or naïve CD8+ T cells. There
was also no mid-mission elevation in constitutively acti-
vated (HLA-DR+) CD4 or CD8 subsets. In fact, levels of
constitutively activated T cells actually declined during the
HMP mission, and were trending upwards towards base-
line by R+60 (figure 5c).
Intracellular cytokine analysis
The only functional assessment conducted during the
HMP mission was an assessment of intracellular cytokine
production by the CD4+ and CD8+ T cell subsets. These
cultures were stimulated for 5 hours in the presence of
PMA and ionomycin, with monensin added to block
extracellular transport and allow intracellular accumula-
tion. Compared to baseline, there was a significant
decline in both the number of IL-2 producing CD4+ and
CD8+T cell subsets mid mission that completely resolved
by R+60 (figure 5d). The percentage of IFNg producing
CD8+ T cells was also significantly reduced. The percent-
age of IFNg producing CD4+ T cells was reduced, but in a
less dramatic fashion that did not achieve statistical signif-
icance. Levels of IFNg producing T cell subsets also did
also resolve by R+60 (figure 5d). It is noteworthy that the
cytokine alterations observed during the mission
appeared to be cytokine-specific, and not specific to any
particular T cell subset.
Plasma viral antibody/DNA levels
To monitor the potential reactivation of latent EBV, levels
of plasma EBV IgG and IgM were determined by immun-
ofluorescence. Interestingly, one of the 10 HMP study par-
ticipants was EBV sero-negative during pre-mission testing
and appeared to remain sero-negative through the mid-
mission assessment. Of the 9 EBV sero-positive individu-
als, 5 demonstrated an increased IgG titer mid-mission as
compared to pre-mission values. However, for all five sub-
jects the increase did not achieve what is usually associ-
ated with true reactivation of EBV (a four-fold increased
titer). The remaining 4 individuals showed no change in
IgG titer (Table 1). The presence of EBV IgM is associated
with active or recent infection/reactivation, and the nor-
mal value is considered negative. One of the 9 participants
Representative flow cytometry scatter plots demonstrated  the analytical integrity of the field-processed mid-mission  samples Figure 4
Representative flow cytometry scatter plots demonstrated 
the analytical integrity of the field-processed mid-mission 
samples. For flow cytometry analysis, whole blood was pre-
served with a non-cross linking preservative. This reagent 
was found to inhibit cellular auto fluorescence, as well as pre-
serve antigenic structure of both extracellular as well as 
intracellular (cytokine) molecules. CD14 vs. side scatter plots 
allowing enumeration of granulocyte, monocyte and lym-
phocyte subsets are presented derived from a CD45+ gate 
to eliminate artifactual debris.BMC Immunology 2007, 8:7 http://www.biomedcentral.com/1471-2172/8/7
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was found to be IgM positive at the pre-mission assess-
ment, and all 10 participants were IgM negative during
mid-mission testing (Table 1). The assessment of plasma
EBV DNA via PCR ('viral load') testing is also a sensitive
indicator of active viral replication. All 10 of the study par-
ticipants were found to be EBV DNA negative at both the
pre-mission and mid-mission timepoints (table 1). Post
mission testing was not performed for these parameters.
Stress hormone levels
Plasma cortisol was assessed in the HMP participants as a
measure of physiological stress. Plasma cortisol is a rela-
tively stable marker that was found to be compatible with
the logistical limitations of the study, including sample
storage and transport conditions. Compared to the pre-
mission baseline assessment, there was a significant
decrease in subject plasma cortisol mid-mission (mean
Mean peripheral blood percentages are plotted for (A) all major major leukocyte subsets; (B) cytotoxic, senescent and naïve  (non-differentiated) CD8+ T cell subsets; and (C) memory (CD45RO+) and constitutively activated (HLA-DR+) CD4+ and  CD8+ T cell subsets Figure 5
Mean peripheral blood percentages are plotted for (A) all major major leukocyte subsets; (B) cytotoxic, senescent and naïve 
(non-differentiated) CD8+ T cell subsets; and (C) memory (CD45RO+) and constitutively activated (HLA-DR+) CD4+ and 
CD8+ T cell subsets. (D) Mean percentages of T cell subsets capable of being stimulated to produce IFNg and IL-2. These data 
are derived from whole blood cultures stimulated with PMA+ionomycin for 5 hours in the presence of monensin to inhibit 
extracellular transport and allow intracellular accumulation. For all plots, mean values are shown without error bars. Data that 
were found to be statistically significant (pre-, vs. mid-) are indicated by '*' and the corresponding 'P' value. All other data were 
not statistically significant. Error bars represent the SEM for each point.BMC Immunology 2007, 8:7 http://www.biomedcentral.com/1471-2172/8/7
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levels 24.5 pg/ml, 15.6 pg/ml respectively; figure 6). Lev-
els were trending towards recovery by R+60 (mean 18.9
pg/ml).
Discussion
The purpose of this study was twofold: (1) to develop and
validate a protocol for collecting, processing and stabiliz-
ing biological samples in remote field locations for
immune assessment testing; and (2) to assess immune sta-
tus in subjects participating in a simulated planetary
exploration (spaceflight) analog. The data generated from
the samples processed on-location demonstrate that a
variety of field immunology laboratory techniques may
be performed in remote settings without access to sophis-
ticated equipment, provided transport to a laboratory for
analysis may be arranged within approximately two weeks
of sample processing. All whole blood cultures, immu-
nophenotype, and plasma assays were successfully per-
formed using the field-collected samples (figure 4).
Immunophenotype was performed at JSC on whole blood
samples that had been preserved on location. Although
this protocol generally functioned well, lengthy delays in
processing of sample tended to result in mildly elevated
levels of green auto fluorescence. Using the cytometry
techniques described above, this artifact did not adversely
affect the data. Subsequent to this study however, the
authors have found that on-location staining, lysing and
fixation of all cytometry samples, followed by storage in
1.0% paraformaldehyde in PBS containing 1.0% non-fat
dry milk significantly reduces the problematic auto fluo-
rescence associated with storage in paraformaldehyde
alone (data not shown). Samples stained for cytometry
analysis in this manner and stored for up to two weeks are
nearly indistinguishable from freshly stained samples.
This is the technique currently employed by NASA when
processing astronaut cytometry samples in Russia follow-
ing landing of the International Space Station crews on
the Russian Soyuz vehicle.
Given the epidemic disease rates in third-world countries,
and the increasing sophistication of clinical laboratory
equipment (limiting field use), we anticipate that proto-
cols such as those validated here may have important
future field research applications. In addition, protocols
such as these could be modified for immune function test-
ing on-orbit, to facilitate space physiology studies
required prior to exploration-class space missions.
Indeed, some of the microgravity-compatible hardware
required to implement such investigations has already
been developed. This study utilized the BCPSA for preser-
vation of leukocytes (figure 7), and our laboratory previ-
ously described the Whole Blood Staining Device for on-
orbit cell staining and whole blood culture [43,44]. Due
to the many barriers to flying standard laboratory equip-
ment in space (size, weight, liquid usage, power require-
ments, microgravity compatibility), a modified approach
similar to the one described here could likely support
immunology research investigations during low Earth
orbit and short duration Lunar missions. Any routine
monitoring during future long duration Lunar and Mars
flights however, will likely require on-board analytical
equipment, as timely sample return will be impossible.
Determining any clinical risk related to the effects of space
flight on the human immune system presents several
daunting challenges. First among these is a lack of in-
flight data. The vast majority of flight immune studies
have been pre-, and post-flight assessments. Unfortu-
nately, post-flight assessments may be skewed by the
effects of landing and readaptation to the 1 × G environ-
ment. Because of this, it is difficult to extrapolate post-
flight data to the in-flight condition. Until comprehensive
studies are initiated to assess in-flight immunity, it is use-
ful to perform ground-based analog studies. The HMP
Mean pre-, mid-, and post-mission plasma cortisol levels for  the HMP-2002 study participants Figure 6
Mean pre-, mid-, and post-mission plasma cortisol levels for 
the HMP-2002 study participants.
Table 1: Subject plasma levels of EBV IgG, EBV IgM and EBV 
DNA before and during HMP deployment.
EBV IgG EBV IgM EBV DNA
SUBJECT PRE MID PRE MID PRE MID
1 640 640 NEG NEG NEG NEG
23 2 0 640 NEG NEG NEG NEG
3 2560 2560 NEG NEG NEG NEG
4 0 0 NEG NEG NEG NEG
53 2 0 640 POS NEG NEG NEG
66 4 0 1280 NEG NEG NEG NEG
7 1280 1280 NEG NEG NEG NEG
86 4 0 1280 NEG NEG NEG NEG
9 1280 1280 NEG NEG NEG NEG
10 640 1280 NEG NEG NEG NEG
Antibody levels were determined by immunofluorescence, DNA 
levels were assessed by PCR. Plasma antibody levels are expressed as 
titer. Post mission assessments were not performed.BMC Immunology 2007, 8:7 http://www.biomedcentral.com/1471-2172/8/7
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represents a potentially good ground-based spaceflight
analogs with regards to flight-associated immune dys-
function. Several likely causes of this phenomenon are
shared between flight and HMP: long difficult travel,
remoteness and isolation, extreme environment, dis-
rupted circadian rhythms, and mission-associated stress.
HMP participants keep rigorous schedules with respect to
actual (not analog) exploration activities, hardware evalu-
ation, and science studies, to maximize the benefit from
their time on Devon Island. The only potential causes of
flight immune dysregulation NOT shared with the HMP
to some degree are high-energy radiation and micrograv-
ity. Interestingly, HMP participants are exposed to ele-
vated levels of ultraviolet radiation due to the thinned
atmospheric ozone concentrations in the Arctic [45],
although it is not expected that short term elevated UV
exposure would influence the parameters measured dur-
ing this study.
The 10 HMP field participants and their environment had
several important features in common with astronauts
serving onboard the International Space Station. Both
groups represent otherwise healthy and fit individuals
performing mission activities in a remote and stressful
environment. We believe that the data generated during
this study accurately reflect what would be anticipated
from such individuals. No consistent changes were
observed in the distribution of any major peripheral leu-
kocyte subsets. The leukocyte differential, lymphocyte
subsets and T cell subsets were essentially unchanged
between the pre-, mid-, and post-mission timepoints (fig-
ure 5a). In addition, no mid-mission changes were
observed between the memory/naïve T cell subsets and no
elevation occurred in the levels of constitutively activated
(HLA-DR+) T cell subsets (figure 5b). Interestingly, the
mean percentage of active cytotoxic (C1.7+/CD28+)
CD8+ T cells did rise during the mission, corresponding to
a decrease in the percentage of non-differentiated (C1.7-/
CD28+) CD8+ T cells (figure 5c). The levels of these CD8+
T cell subsets resolved to baseline levels post-mission. The
C1.7+/CD28+ subsets of CD8+ T cells is associated with
higher cytotoxic activity and interferon-gamma produc-
tion, and this subset is thought to control viral infections
by mediating cytolytic activity against viral infected cells.
As none of the participants demonstrated any mid-mis-
sion symptoms and no infections were reported, it is pos-
sible that the mid-mission associated rise in this subset is
associated with latent viral reactivation or some other sub-
clinical effect.
We believe that the immune subset data is consistent with
otherwise healthy individuals in a stressful environment,
and that these changes do not relate to the presence or
absence of immune functional changes. Indeed, when a
legitimate indicator of immune function was assessed, the
cytokine profiles of the T cell subsets, sharp mission-asso-
ciated decreases were observed. The ability of the T cell
subsets (CD4+ and CD8+) to be stimulated to produce
Interleukin-2 was significantly decreased mid-mission, as
was the CD8+ population that could be stimulated to pro-
duce IFNg (figure 5d). All functional changes resolved
back to near baseline values by the post-mission time-
point.
One consistent in-flight observation in astronauts is that
the reactivation of latent herpes viruses occurs during
spaceflight to high levels [19-22]. It is thought that the
reactivation of these latent viruses may be a direct conse-
quence to diminished immune function, as a healthy
immune system is responsible for controlling these exac-
erbations. Latent viral reactivation is also known to occur
during terrestrial stress situations. Plasma EBV antibody
levels and direct viral DNA were assessed in the 10 HMP
participants to determine if viral reactivation occurred
during the mission. It is noteworthy that in the time fol-
lowing this study, better technology has evolved for mon-
itoring viral specific immunity, such as tetramer
quantitation of virus specific T cells, and peptide stimula-
tion to monitor virus-specific T cell function [46]. In the
The Blood Collection/Preservation/Storage Apparatus  (BCPSA) designed to safely preserve of whole blood samples  during microgravity conditions Figure 7
The Blood Collection/Preservation/Storage Apparatus 
(BCPSA) designed to safely preserve of whole blood samples 
during microgravity conditions. Whole blood is collected 
into a Monovette containing anticoagulant, and is transferred 
to a Monovette containing preservative via a novel interlink 
adaptor. Use of this device is highly advantageous during 
microgravity or field studies, as it greatly simplifies opera-
tions, reduces operator time and improves safety by nearly 
eliminating exposure to liquid blood samples. This device was 
validated during microgravity conditions onboard the NASA 
KC-135 parabolic flight aircraft in 2000, and utilized during 
the HMP 2002 immune study. Top and lower left: BCPSA in 
use at Devon Island; lower right: BCPSA evaluation during 
reduced gravity.BMC Immunology 2007, 8:7 http://www.biomedcentral.com/1471-2172/8/7
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HMP study subjects, 5 of 9 seropositve individuals did
show an increase in plasma EBV IgG titers (Table 1).
Although this could be an indicator of increased viral reac-
tivation, none of the subjects were EBV IgM positive dur-
ing the study, and none were positive for plasma EBV
DNA. Based on this data, it cannot be said conclusively
that any EBV reactivation occurred during the HMP mis-
sion. Future studies (incorporating assays such as tetramer
staining and peptide stimulation) would be required to
determine more precisely if low level latent viral reactiva-
tion occurs during HMP deployment.
It is well established that periods of physiological stress
correlate with dysregulated immune function [47]. Classi-
cal dogma indicated that stress is immunosuppressive, via
activation of the HPA axis and elevated levels of stress hor-
mones. Corticosteroids have been demonstrated to sup-
press the function of immune cells, trafficking of
leukocytes and cytokine production [47]. More recent
studies however, show that certain types of acute stress
may actually enhance immunity. Skin DTH responses are
depressed following chronic stress, but are elevated fol-
lowing acute (2 h) stress [48]. In addition, the major stress
hormones inhibit systemic IL-12, TNFa and IFNg (Th1
cytokines), but actually upregulate IL-10, IL-4 (Th2
cytokines) [49]. Thus, stress may be associated with a Th2
shift, postulated to protect the organism from 'overshoot-
ing' an inflammatory response. In fact, the neuro-immune
interactions are extremely complex and specific effects
depend largely on the type and duration of the stressful
event.
Spaceflight itself may be a physiological stressor, and cer-
tainly landing, with a high-G entry and readaptation to
the 1 × G environment after lengthy microgravity decon-
ditioning, is a tremendous physiological stress. Following
spaceflight, alterations in stress hormones have been
observed in astronauts. Stowe et al. found that following
spaceflight of 8–15 days there was no change in plasma
cortisol or adrenocorticotropic hormone levels. In con-
trast, urinary epinephrine, norepinephrine and cortisol
were significantly elevated following flight [18]. A more
recent study found that mission duration had an effect on
the levels of stress hormones following flight. After a 9 day
mission, plasma cortisol was significantly decreased; how-
ever after a 16 day mission levels were significantly
increased [31]. In contrast, urinary epinephrine and nore-
pinephrine levels were greater after the shorter duration
mission [31]. The conclusion was that shorter (acute) mis-
sions were characterized by a sympathetic response;
whereas longer flight may be characterized by a glucocor-
ticoid-mediated change related to longer microgravity
duration. In the HMP participants, plasma cortisol was
assessed as a measure of physiological stress. This hor-
mone is stable enough following plasma purification,
storage for the duration necessary, and sample return for
subsequent analysis. The collection of 24-hour urine sam-
ples was unfortunately not considered realistic during the
2002 deployment, considering the other exploration
activities being performed by the subjects. The significant
decrease in plasma cortisol observed during the HMP mis-
sion (figure 6) is identical to the data derived from astro-
nauts following 9 day spaceflight [31]. Considering the
environmental conditions on Devon Island and the
immune function data (figure 5d), it seems likely that the
decreased plasma cortisol may be an indicator of the phys-
iological stress related to deployment to Devon Island.
These data may have correlated with an increased urinary
cortisol level (had it been performed) and as observed in
astronauts following the 16 day spaceflight [31]. The
authors believe that reduced levels of plasma cortisol fol-
lowing a stressful event, in contrast to more persistent ele-
vated urine levels, may represent a 'rebound' effect as the
body re-adapts after the initial acute stress response.
Essentially, the acute rise in plasma cortisol occurs rapidly
after a stress event, and is quickly followed by recovery to
baseline or even depressed levels. To derive a better under-
standing of the physiological stress aspects of this flight
analog, it would be desirable to include a 24 hour urine
collection and processing in any future HMP human
physiology study.
Taken together, these data support the establishment of
the HMP as a unique ground-based spaceflight/planetary
exploration analog that may have significant utility for
terrestrial human physiology studies. The HMP may be
particularly useful for assessments of human physiology
such as immunology, that are particularly influenced by
stress, isolation and disrupted circadian rhythms.
Methods
Study design/subjects
This study protocol was designed to be analogous to
spaceflight research: baseline testing was performed 30–
60 days prior to the start of the mission to establish base-
line values; mid-mission testing performed to assess mis-
sion-associated changes; and post-mission testing
performed 30–60 days after return to confirm recovery to
baseline values. Ten healthy male subjects scheduled to
participate in the HMP-2002 field season were enrolled in
this study. No female HMP 2002 participants were identi-
fied who could be solicited for this study, primarily for
logistical reasons. The subjects were from a variety of loca-
tions and institutions located throughout the US and Can-
ada (figure 1a). On Devon Island the subjects lived in
standard cold weather tents (see figure 2) and generally
worked long days participating in exploration activities.
Subjects generally ate well, with meals provided by the
HMP facility. Approval from the Johnson Space Center
Committee for the Protection of Human Subjects (CPHS)BMC Immunology 2007, 8:7 http://www.biomedcentral.com/1471-2172/8/7
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was obtained prior to the initiation of the study. Informed
consent was obtained from each subject prior to participa-
tion in the study.
Whole blood samples
Whole blood samples consisted of 10.0 ml EDTA and
10.0 ml heparin whole blood collected per subject per
timepoint using standard phlebotomy techniques during
the morning hours. Because it was necessary to collect pre-
and post-mission samples near the local residence of the
subject, clinical laboratories from local hospitals were
enlisted to perform the pre- and post-mission sample col-
lections. Pre- and post-mission samples were shipped
overnight to JSC for analysis. Previous in-house validation
has shown that a 24-hour delay in sample processing did
not affect the results for the parameters measured during
this study (data not shown). For consistency of data, all
mid-mission blood samples collected on Devon Island
were held for 24 hours in the laboratory tent at ambient
temperature (heated, approximately 15–22 degrees C)
prior to processing to duplicate the pre- and post-mission
sample shipping delays. Specific sample collection points
for each subject are presented in figure 3.
Immunophenotype analysis
A 5-color flow cytometry antibody matrix was created
(using FITC, PE, PE-Texas Red, PC5 and APC as fluoro-
chromes) that assessed most of the major leukocyte/lym-
phocyte subsets, as well as various memory/naïve and
activated T cell subsets (see table 2). All labeled antibodies
were obtained from Beckman Coulter Corporation,
Miami, Florida, or Becton Dickinson, Franklin Lakes, NJ,
and were used according to the manufacturer's instruc-
tions. Cell surface markers were stained first combining
100 ul of EDTA whole blood and 10 µg of each appropri-
ate labeled monoclonal antibody. Staining was performed
by incubated the mixture at room temperature for 20 min-
utes. Red blood cells were lysed using Beckman-Coulter
optilyse as described by the manufacturer. Stained leuko-
cytes were then fixed in 1.0% paraformaldehyde in PBS
for 10 minutes prior to analysis. Analysis was performed
on a Beckman-Coulter ALTRA Cytometer configured for 5
color analysis using argon and HeNe dual lasers. All com-
mon leukocyte sub populations were analyzed: granulo-
cytes, lymphocytes, monocytes, T cell CD4/CD8 subsets,
effector/cytotoxic CD8+ subsets, memory/naïve
(CD45RA-/+) and activated T cell subsets (HLA-DR+).
Modifications to this procedure during activities on
Devon Island are described below.
Intracellular cytokine analysis
Lymphocyte intracellular cytokine profiles were assessed
for specific cell subsets at the single-cell level utilizing
intracellular flow cytometry. The unique advantage of this
technique is the ability to assess the production of multi-
ple cytokines simultaneously in positively identified cell
sub-populations using multi-color flow analysis. Whole
blood culture was performed to eliminate the need for cell
purification steps [43]. Also, whole blood culture may
also represent more accurately in-vivo responses since all
cell types are present to preserve cell-cell reactions, as well
as any soluble factors present in the plasma. Cultures were
set up by adding 100 ul of heparinized whole blood to 1.0
ml of RPMI culture media. A combination of PMA (10 ng/
ml) and Ionomycin (10 ug/ml) was used for T cell stimu-
lation with monensin (3.0 uM) added to the cultures to
halt the extracellular transport of cytokines and allow
intracellular accumulation to detectable levels. Cultures
were incubated for 5 hours at 37 degrees Centigrade. Fol-
lowing culture, the activated blood was washed, superna-
tants were removed, the RBCs lysed as noted above, and
the remaining WBCs were fixed in 4.0% paraformalde-
hyde for 10 minutes. To detect intracellular production of
IFNγ or IL-2 (following surface marker staining), the fixed
PBMC's were resuspended in 200 µl of permeabilization
buffer, consisting of 5.0% non-fat dry milk and 0.5%
saponin in PBS to which 0.5 µg of labeled mouse anti-
body to either IFNγ or IL-2 (or both) was added. The cells
Table 2: Fluorescent antibody panel for the 2002 Haughton Mars Immune Assessment
FITC PE ECD PE/Cy5 APC CELL POPULATIONS
CD14 (RMO52) CD45 (J.33) WBC differential:  granulocytes/lymphocytes/
monocytes
CD3 (UCHT1) CD16 (3G8) CD19 (J4.119) CD45 (J.33) Lymphocyte subsets: T cells, B cells and NK cells
CD4 (13B8.2) CD8 (B9.11) CD3 (UCHT1) T cell subsets: CD4+ vs. CD8+
CD45RA (ALB11) CD45RO (UCHL1) CD4 (13B8.2) CD3 (UCHT1) Naïve/memory CD4+ T cell subsets
CD45RA (ALB11) CD45RO (UCHL1) CD8 (B9.11) CD3 (UCHT1) Naïve/memory CD8+ T cell subsets
CD8 (B9.11) CD28 (CD28.2) CD244 (C1.7) CD3 (UCHT1) Cytotoxic effector/suppressor CD8+ T cell 
subsets
HLA-DR (Immu-357) CD69 (TP1.55.3)  CD8 (B9.11) CD4 (13B8.2) CD3 (UCHT1) Activation status of T cell subsets (CD4/CD8+)
IFNg* (5344.111) IL-2* (25723.11) CD8 (B9.11) CD3 (UCHT1) Intracellular detection of cytokines in T cell 
subsets
All antibodies purchased from either the Beckman-Coulter Corporation except for (*), purchased from  Dickinson. The specific antibody clones are 
indicated in parentheses.BMC Immunology 2007, 8:7 http://www.biomedcentral.com/1471-2172/8/7
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were incubated at room temperature for 25 minutes and
then washed in PBS containing saponin. The cells were
then resuspended in 1.0% paraformaldehyde for analysis.
EBV antibody levels
EBV VCA IgG testing was performed using the Merifluor
EBV IgG IFA kit (Meridian Bioscience, Inc., Cincinnati,
OH) according to the manufacturer's instructions. EBV
IgM antibody was detected using the Diamedix EBV VCA
IgM assay (Diamedix, Inc, Miami, FL) according to the
manufacturer's instructions on the MAGO automated
microplate robotic system (Diamedix).
EBV plasma viral load
EBV PCR was performed by real time PCR using primers/
probe set first described by Kimura, H. et al. [50]. 200
microliters of whole blood was processed using the Qia-
gen Blood DNA kit according to the manufacturer's
instructions. Five microliters of the eluted DNA was added
to a PCR master mix prepared using the TaqMan Universal
PCR Master Mix, no AmpErase UNG (Applied Biosystems,
Foster City, CA), uracil-N-glycosylase (UNG) from Epi-
centre Inc. and the EBV specific primers (100 nmolar) and
probe (200 nmolar). Real time PCR was performed using
an ABI 7000 SDS (Applied Biosystems) with cycling con-
ditions of 37 degrees C for 10 minutes, 95 degrees C for
10 minutes and 50 cycles of 95 degrees for 15 seconds and
60 degrees C for 60 seconds. Sensitivity of the PCR was
determined to be 5 input copies which equates to approx-
imately 250 copies per ml of whole blood.
Plasma cortisol levels
The measurement of plasma cortisol was performed by
enzyme-linked immunosorbant assay (Diagnostic Sys-
tems Laboratories, Webster, Texas) as has previously been
described in detail [18,51].
Field sample processing protocol
No laboratory equipment was transported for real-time
field analysis. Instead, techniques were developed allow-
ing field culture, processing and preservation of samples
for subsequent laboratory analysis after mission comple-
tion. In general, the field activities consisted of the follow-
ing activities:
• Collection of whole blood samples.
• Setup of whole blood culture for T cell activation.
• Preservation of whole blood for flow cytometry assays.
• Preservation of activated leukocytes for intracellular
cytokine detection.
• Purification and aliquoting of plasma for stress hor-
mone and viral assays.
The sample processing performed on Devon Island ren-
dered all sample types stable for storage and transport to
JSC for subsequent analysis. During the deployment,
processing was aided by the development of novel hard-
ware for processing blood samples, the use of a newly
developed commercial leukocyte preservatives and the
development of field sample processing techniques. In
most cases, processing rendered the samples stable for up
to two weeks without cold storage allowing easy transport
off Devon Island for subsequent analysis at Johnson Space
Center. The individual modifications for field use per
assay are as follows:
Field blood collection
On Devon Island, a phlebotomy station was set up in the
main laboratory tent. Samples were collected from each
subject by venipuncture using sterile techniques and but-
terfly type collection equipment. This does not represent
a significant deviation from standard blood collection
techniques.
Field leukocyte subset analysis
Whole blood was treated with a recently developed com-
mercial preservative (Cytochex, Streck Laboratories Inc.)
[52] that maintains the antigenic structure of the cell sur-
face molecules for at least 7–31 days [53,54]. For this
study our laboratory validated that samples may be stored
chilled for up to two weeks with out loss of subset resolu-
tion by flow cytometry (data not shown). Representative
scatter plots demonstrating no loss of subset discrimina-
tion are presented in figure 4. Typical long-term storage of
paraformaldehyde fixed samples for flow cytometry anal-
ysis (> 2 days) results in a marked increase in green auto-
fluorescence that may hinder analysis. The Cytochex pre-
servative is non-crosslinking, which was found to greatly
reduce the problematic autofluorescence associated with
samples stored long term in only paraformaldehyde.
There are however several markers that are largely or
totally incompatible with this preservative. CD19 staining
is diminished, and CD62L is rendered unstainable follow-
ing Cytochex treatment. For markers such as these, the
only option is to actually stain the cell samples in stand-
ard fashion and preserve until analysis.
Field blood preservation hardware
To facilitate field sample processing, and to reduce the
amount of biohazardous waste, whole blood preservation
was performed on Devon Island using the Blood Collec-
tion/Preservation/Storage Apparatus (BCPSA) (Figure 7).
This device consists of a Monovette preloaded with pre-
servative, a second anticoagulated Monovette for blood
sample collection, and a novel interlink adapter. Via con-BMC Immunology 2007, 8:7 http://www.biomedcentral.com/1471-2172/8/7
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nection of the interlink adaptor, it is possible to quickly
and easily transfer whole blood into the liquid preserva-
tive. The adaptor is then removed and discarded, and the
storage vessel stem is removed, creating a stable long-term
storage environment for the preserved blood. The BCPSA
functions in a completely microgravity-compatible fash-
ion, and was developed for potential future sample
processing onboard the International Space Station.
Microgravity validation of this device was performed
onboard the NASA KC-135 reduced gravity aircraft in
2000 (Figure 7). The BCPSA would be advantageous for
use in other field clinical studies, particularly those
involving infectious disease, where it is desirous not to
manually pipette potentially infectious blood samples.
Use of the BCPSA completely protects the user from acci-
dental exposure to the liquid blood sample during
processing.
Field cell culture protocol
All cell culture reagents were transported to Devon Island
chilled and stored chilled until use. Previous in-house
testing has validated the stability of all the cell culture
mitogens (PMA, ionomycin, monensin) without loss of
activity for up to two weeks when stored in this manner
(data not shown). Typical laboratory incubators supply
two items to the incubating cells: 37 degree heat, and
CO2. Since short term culture in buffered media does not
require exogenous CO2, whole blood cultures were per-
formed on Devon Island in 12 × 16 mm polystyrene tubes
that were tightly sealed. A similar method for whole blood
culture in portable devices was previously described [43].
A portable field incubator was developed consisting of a
small soft-side insulated box and a heating coil capable of
holding 37°C. Temperature was monitored throughout
the incubation and did not deviate +/- 2 degrees from
37°C. Finally, we have found that the performance of
short term cultures such as these precludes the need to set
up the cultures in a biological safety cabinet for sterility
(for most assays). Prior to the HMP mission, parallel stud-
ies found that intracellular cytokine cultures and analysis
setup using standard laboratory techniques (CO2 expo-
sure, sterile hood, etc.) and the field technique were indis-
tinguishable (data not shown). Following culture, the
supernatant was removed and the activated cells were pre-
served by the addition of 500 ul of Cytochex preservative
for transport to JSC. Previous in-lab validation had dem-
onstrated that this reagent preserved the intracellular
cytokines as well as the surface antigens at room tempera-
ture without the need for cold storage. Preserved activated
cell samples were stored either at room temperature or 4
degrees 37°C during storage on-location or during trans-
port to JSC for analysis.
Field plasma separation and storage
To purify and aliquot EDTA plasma on-location at Devon
Island for viral and cortisol assays, a small centrifuge was
transported to the island. EDTA whole blood was centri-
fuged for 10 minutes, and plasma was removed and
stored in labeled cryo-vials. Plasma samples were stored at
4–5°C when possible, and briefly at room temperature
otherwise (during air travel), for transport to JSC for anal-
ysis. Salivary cortisol has been found to be extremely sta-
ble when stored at 5°C, with values unchanged following
storage of up to 3 months [55]. We have validated that
plasma cortisol is stable at room temperature for up to 2
weeks (data not shown).
Statistical analysis
To determine mission-associated alterations, mid-mission
data were compared to pre-mission baseline values. Statis-
tical operations were performed by using Microsoft Excel
2003. The Student's paired t test was used and p values of
less than 0.05 were considered significant. Where appro-
priate, significant data is indicated by '*'.
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